FGF1 and type 2 diabetes mellitus: Support for this hypothesis includes evidence from 3 different mouse models of T2D, which show that sustained glucose lowering induced by i.c.v. FGF1 injection is blocked when Mc4r signaling is disrupted by either genetic or pharmacological means (16).